SK Bioscience opens W377b R&D center in Songdo

Kan Hyeong-woo 2026. 1. 19. 15:08
음성재생 설정 이동 통신망에서 음성 재생 시 데이터 요금이 발생할 수 있습니다. 글자 수 10,000자 초과 시 일부만 음성으로 제공합니다.
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

New office expected to bolster global partnerships
SK Bioscience's newly opened global research and process development center in Songdo, Incheon. (SK Bioscience)

SK Bioscience has officially opened its new global research and process development center in Songdo, Incheon, where Korea’s biopharmaceutical sector has a substantial presence, the company said Monday.

SK Bioscience invested a total of 377.2 billion won in the newly opened facility, which spans 64,000 square meters in floor area with two underground and seven above-ground levels.

The company highlighted that the new site features the country’s largest vaccine-focused research labs. In them, researchers can explore next-generation vaccine platforms — including mRNA, recombinant protein and viral vector technologies — in an advanced digital working environment.

The new facility features a world-class pilot lab for a one-stop development system that can carry out early-stage platform research, the design process, scaling up and verifying technologies, to enhance the speed of development and the level of completion.

SK Bioscience emphasized the areas for business meetings, such as an open space that can accommodate over 100 people for various events involving global partners, as well as representatives from governments and international organizations. It also offers a viewing hallway outside the pilot lab where visitors can observe the research and development process.

Songdo is home to Korea’s leading contract development and manufacturing organization company Samsung Biologics and top biosimilar firm Celltrion, as well as the Korean offices of global pharmaceutical giants such as Janssen, Merck Life Science and Sartorius.

“The move into the Songdo global (research and process development center) goes beyond a simple relocation of offices, representing the establishment of core infrastructure to practically implement SK Bioscience’s mid- to long-term growth strategy,” said SK Bioscience CEO Ahn Jae-yong.

“Based on this site, we will continue driving innovation to become a global company that contributes to enhancing the world’s public health by connecting research, process development and global cooperation as a single growth structure.”

Copyright © 코리아헤럴드. 무단전재 및 재배포 금지.